Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)

Table 1 (abstract P238). Characteristics and results of the included JIA patients

	Immediate stop, N =27¹	Taper, N = 28¹	p-value²
Response	20 (74%)	23 (82%)	0.5
Sex, Female	17 (63%)	14 (50%)	0.3
Age (years)	10.0 (7.9, 13.9)	14.0 (10.7, 16.7)	0.5
TNFi-free period before re-treatment (months)	6.2 (4.0, 8.9)	5.1 (2.4, 12.4)	0.020
Active Joint Count	3.0 (1.0, 5.50)	1.0 (0.8, 2.2)	0.012

¹ n (%); Median (IQR). TNFi = trumor necrosis factor inhibitor
² Pearson’s Chi-squared test for categorical data; Wilcoxon rank sum test for numeric data

ISSN: 1546-0096